These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26645975)

  • 21. Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States.
    Patel HD; Gupta M; Joice GA; Srivastava A; Alam R; Allaf ME; Pierorazio PM
    Eur Urol Oncol; 2019 Jul; 2(4):343-348. PubMed ID: 31277771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
    Gigante M; Li G; Ferlay C; Perol D; Blanc E; Paul S; Zhao A; Tostain J; Escudier B; Negrier S; Genin C
    Anticancer Res; 2012 Dec; 32(12):5447-51. PubMed ID: 23225450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.
    Sierra PS; Cordeiro MD; Albuquerque EV; Bastos DA; Bonadio RC; Sarkis AS; Cavalcante A; Pontes J; Coelho RF; Nahas WC
    Clin Genitourin Cancer; 2020 Apr; 18(2):e134-e144. PubMed ID: 31980410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
    Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
    Motzer RJ; Nosov D; Eisen T; Bondarenko I; Lesovoy V; Lipatov O; Tomczak P; Lyulko O; Alyasova A; Harza M; Kogan M; Alekseev BY; Sternberg CN; Szczylik C; Cella D; Ivanescu C; Krivoshik A; Strahs A; Esteves B; Berkenblit A; Hutson TE
    J Clin Oncol; 2013 Oct; 31(30):3791-9. PubMed ID: 24019545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).
    Aizer AA; Urun Y; McKay RR; Kibel AS; Nguyen PL; Choueiri TK
    BJU Int; 2014 May; 113(5b):E67-74. PubMed ID: 24053727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.
    Richey SL; Culp SH; Jonasch E; Corn PG; Pagliaro LC; Tamboli P; Patel KK; Matin SF; Wood CG; Tannir NM
    Ann Oncol; 2011 May; 22(5):1048-1053. PubMed ID: 21115604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population.
    Breda A; Lucarelli G; Rodriguez-Faba O; Guirado L; Facundo C; Bettocchi C; Gesualdo L; Castellano G; Grandaliano G; Battaglia M; Palou J; Ditonno P; Villavicencio H
    World J Urol; 2015 Jan; 33(1):1-7. PubMed ID: 24504760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.
    Culp SH; Karam JA; Wood CG
    Urol Oncol; 2014 Jul; 32(5):561-8. PubMed ID: 24709415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
    Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
    Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
    Guram K; Huang J; Mouchati C; Abdallah N; Jani C; Navani V; Xie W; El Zarif T; Adib E; Gebrael G; Agarwal N; Li H; Labaki C; Labban M; Ruiz Morales JM; Choueiri TK; Chin Heng DY; Mittal A; Hansen AR; Rose BS; McKay RR
    Cancer; 2024 Jun; 130(11):2003-2013. PubMed ID: 38297953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
    Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
    BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Renal Cell Carcinoma in England: A Retrospective Cohort Study.
    Das P; Booth A; Donaldson R; Berfeld N; Nordstrom B; Carroll R; Dhokia P; Clark A; Vaz L
    Clin Genitourin Cancer; 2024 Jun; 22(3):102081. PubMed ID: 38641444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.
    Thornton Snider J; Batt K; Wu Y; Tebeka MG; Seabury S
    Am J Manag Care; 2017 Oct; 23(10):e340-e346. PubMed ID: 29087638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival.
    Patel MI; Beattie K; Bang A; Gurney H; Smith DP
    Cancer Med; 2017 Oct; 6(10):2188-2193. PubMed ID: 28834281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma.
    Shao Y; Xiong S; Sun G; Dou W; Hu X; Yang W; Lia T; Deng S; Wei Q; Zeng H; Li X
    Cancer Med; 2020 Feb; 9(3):959-970. PubMed ID: 31840431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
    Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
    BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.